25 related articles for article (PubMed ID: 29407309)
1. Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas.
Heijnsdijk EAM; Gulati R; Lange JM; Tsodikov A; Roberts R; Etzioni R
JAMA Health Forum; 2022 May; 3(5):e221116. PubMed ID: 35977253
[TBL] [Abstract][Full Text] [Related]
2. Examination of the Brain-Dead Organ Donor Management Process at a Spanish Hospital.
Sánchez-Vallejo A; Gómez-Salgado J; Fernández-Martínez MN; Fernández-García D
Int J Environ Res Public Health; 2018 Oct; 15(10):. PubMed ID: 30287725
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?
Faiena I; Holden S; Cooperberg MR; Holden S; Soule HR; Simons JW; Morgan TM; Penson DF; Morgans AK; Hussain M
J Clin Oncol; 2018 Apr; 36(10):937-941. PubMed ID: 29401003
[No Abstract] [Full Text] [Related]
4. [Evaluation of serum PSA in brain-dead subjects over the age of 50 before organ harvesting: organ donation and the risk of transmission of prostate cancer. Survey of the transplantation committee of the Association Francaise d'Urologie].
Salomon L; Feuillu B; Petit J; Sallusto F; Lechevallier E; Eschwege P;
Prog Urol; 2007 Jun; 17(4):828-31. PubMed ID: 17633995
[TBL] [Abstract][Full Text] [Related]
5. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
Kim HS; Jeon SS; Choi JD; Kim W; Han DH; Jeong BC; Seo SI; Lee KS; Lee SW; Lee HM; Choi HY
Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152
[TBL] [Abstract][Full Text] [Related]
6. Saturation biopsies for prostate cancer detection: effectiveness, safety and predictive factors.
Utrera NM; Sánchez AT; Rodríguez-Antolín A; Martín-Parada A; Lora D; Passas J; González RD
Arch Esp Urol; 2011 Jun; 64(5):421-6. PubMed ID: 21705814
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implication of Tests for Prostate-specific Antigen in Brain-dead Organ Donors.
Lee GW; Lee JM; Lee WJ; Kim YB; Min YG
Transplant Proc; 2018; 50(1):20-23. PubMed ID: 29407309
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the pathologic results of prostate biopsies in terms of age, Gleason score and PSA level: our experience and review of the literature.
Sarıkaya S; Resorlu M; Oguz U; Yordam M; Bozkurt OF; Unsal A
Arch Ital Urol Androl; 2014 Dec; 86(4):288-90. PubMed ID: 25641453
[TBL] [Abstract][Full Text] [Related]
11. The clinical usefulness of prostate specific antigen: update 1994.
Partin AW; Oesterling JE
J Urol; 1994 Nov; 152(5 Pt 1):1358-68. PubMed ID: 7523702
[TBL] [Abstract][Full Text] [Related]
12. Novel guidelines for organ donor cancer screening.
Hassanain M
Ann Transplant; 2014 May; 19():241-7. PubMed ID: 24841765
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
